Evaluación de la satisfacción con inmunoterapia por vía subcutánea mediante el cuestionario ESPIA en pacientes pediátricos con asma de fenotipo alérgico.

Saved in:

Bibliographic Details
Title:	Evaluación de la satisfacción con inmunoterapia por vía subcutánea mediante el cuestionario ESPIA en pacientes pediátricos con asma de fenotipo alérgico.
Alternate Title:	Satisfaction assessment with subcutaneous immunotherapy a by ESPIA questionnaire in a pediatric population with allergic phenotype asthma.
Authors:	Hernández Romero, Javier¹, Collado Chagoya, Rodrigo¹ rodnova87@hotmail.com, Velasco Medina, Andrea¹, Velázquez Sámano, Guillermo¹, Delgado Martinez, Omar²
Source:	Revista Alergia de Mexico. Apr-Jun2026, Vol. 73 Issue 2, p120-128. 9p.
Abstract (English):	OBJECTIVE: Assess satisfaction with subcutaneous immunotherapy in patients with asthma, by using the Satisfaction Scale for Patients Receiving Allergen Immunotherapy (ESPIA) questionnaire which was validated in Spanish language. METHODS: A cross-sectional, observational, unicenter study was carried out in a National Allergy Reference Center in Mexico in patients older than 6 years of age, diagnosed with Allergic Asthma with positive allergy biomarkers (IgE, Skin Tests, Nasal Mucus Cytology, Eosinophils in Blood) with a mild or moderate severity classification with a Subcutaneous Immunotherapy scheme lasting a minimum of 12 months. The level of satisfaction was assessed during the treatment by the ESPIA questionnaire, and the level of control was measured by using the Asthma Control Test. The correlation between the characteristics of the population, the control of the disease, the severity of the disease and the satisfaction with the treatment was analyzed using the ANOVA test (categorical variables) or the Pearson and Spearman coefficients correlation (continuous variables). RESULTS: A total of 147 patients (mean age 10.08 years, range 4-17 years, 82 men [56%]) were included in the study. Among them 122 (82.9%) suffered some type of comorbidity. The average Score of the ESPIA questionnaire to measure Satisfaction of treatment with Subcutaneous Immunotherapy was 87.12. No statistical differences were found in treatment satisfaction between men and women (p>0.05) and between polysensitized patients with more than 3 allergens and with less than 3 allergens. (p>0.05). There was a lower level of satisfaction with Immunotherapy measured with the ESPIA questionnaire in patients with comorbidity of Atopic Dermatitis. A correlation was demonstrated between levels of disease control and levels of satisfaction with treatment with Subcutaneous Immunotherapy measured with the ESPIA Questionnaire. CONCLUSION: Subcutaneous allergen immunotherapy was associated with high treatment satisfaction in pediatric patients with allergic asthma. Treatment satisfaction showed a positive correlation with asthma control, supporting the clinical relevance of patient-reported outcomes in the evaluation of immunotherapy effectiveness. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	OBJETIVO: Evaluar el grado de satisfacción de la inmunoterapia por vía subcutánea en pacientes pediátricos con asma, mediante el cuestionario ESPIA (Escala de Satisfacción para Pacientes que Reciben Inmunoterapia con Alérgenos), validado en español. MÉTODOS: Estudio transversal, observacional y unicéntrico, llevado a cabo en un centro nacional de referencia de alergia en México, con pacientes mayores de 6 años, diagnosticados de asma alérgica con biomarcadores positivos (IgE, pruebas cutáneas, citología de moco nasal, eosinófilos en sangre) de gravedad leve o moderada, que recibieron un esquema de inmunoterapia por vía subcutánea con duración mínima de 12 meses. El grado de satisfacción se evaluó con el cuestionario ESPIA, y el control mediante la Prueba de Control del Asma. Se analizó la correlación entre las características de la población, el control de la enfermedad, la gravedad de la enfermedad y la satisfacción con el tratamiento mediante la prueba ANOVA (variables categóricas) o los coeficientes de correlación de Pearson y Spearman (variables continuas). RESULTADOS: Se incluyeron 147 pacientes (edad media 10.08 años, rango 4-17 años, 82 hombres [56%]), de los que 122 (82.9%) tuvieron algún tipo de comorbilidad. La puntuación media del cuestionario ESPIA fue de 87.12. No se encontraron diferencias estadísticamente significativas en la satisfacción con el tratamiento entre hombres y mujeres (p>0.05) ni entre pacientes polisensibilizados con más o menos de 3 de 3 alérgenos (p>0.05). Se observó un menor grado de satisfacción con la inmunoterapia, con el cuestionario ESPIA, en pacientes con dermatitis atópica como comorbilidad. Se demostró una correlación entre el control de la enfermedad y la satisfacción con el tratamiento mediante inmunoterapia subcutánea, medida con el cuestionario ESPIA. CONCLUSIÓN: La inmunoterapia subcutánea con alérgenos se asoció con alto grado de satisfacción en pacientes pediátricos con asma alérgica. La satisfacción con el tratamiento mostró una correlación positiva con el control del asma, lo que respalda la relevancia clínica de la eficacia de la inmunoterapia. [ABSTRACT FROM AUTHOR]
	Copyright of Revista Alergia de Mexico is the property of Coleg. Mexicano de Inmunologia Clinica y Alergia A.C.; Soc. Lat. de Alergia, Asma e Inmunologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	OBJECTIVE: Assess satisfaction with subcutaneous immunotherapy in patients with asthma, by using the Satisfaction Scale for Patients Receiving Allergen Immunotherapy (ESPIA) questionnaire which was validated in Spanish language. METHODS: A cross-sectional, observational, unicenter study was carried out in a National Allergy Reference Center in Mexico in patients older than 6 years of age, diagnosed with Allergic Asthma with positive allergy biomarkers (IgE, Skin Tests, Nasal Mucus Cytology, Eosinophils in Blood) with a mild or moderate severity classification with a Subcutaneous Immunotherapy scheme lasting a minimum of 12 months. The level of satisfaction was assessed during the treatment by the ESPIA questionnaire, and the level of control was measured by using the Asthma Control Test. The correlation between the characteristics of the population, the control of the disease, the severity of the disease and the satisfaction with the treatment was analyzed using the ANOVA test (categorical variables) or the Pearson and Spearman coefficients correlation (continuous variables). RESULTS: A total of 147 patients (mean age 10.08 years, range 4-17 years, 82 men [56%]) were included in the study. Among them 122 (82.9%) suffered some type of comorbidity. The average Score of the ESPIA questionnaire to measure Satisfaction of treatment with Subcutaneous Immunotherapy was 87.12. No statistical differences were found in treatment satisfaction between men and women (p>0.05) and between polysensitized patients with more than 3 allergens and with less than 3 allergens. (p>0.05). There was a lower level of satisfaction with Immunotherapy measured with the ESPIA questionnaire in patients with comorbidity of Atopic Dermatitis. A correlation was demonstrated between levels of disease control and levels of satisfaction with treatment with Subcutaneous Immunotherapy measured with the ESPIA Questionnaire. CONCLUSION: Subcutaneous allergen immunotherapy was associated with high treatment satisfaction in pediatric patients with allergic asthma. Treatment satisfaction showed a positive correlation with asthma control, supporting the clinical relevance of patient-reported outcomes in the evaluation of immunotherapy effectiveness. [ABSTRACT FROM AUTHOR]
ISSN:	00025151
DOI:	10.29262/ram.v73i2.1591